Sangamo Therapeutics, Inc. (0R1D.L)
USD 2.62
(-3.68%)
USD 2.62
(-3.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -274 Million USD | 43.22% |
| 2022 | -201.28 Million USD | -9.79% |
| 2021 | -183.33 Million USD | -41.52% |
| 2020 | -129.55 Million USD | -23.17% |
| 2019 | -105.18 Million USD | -36.33% |
| 2018 | -77.15 Million USD | -36.89% |
| 2017 | -56.36 Million USD | 22.32% |
| 2016 | -72.55 Million USD | -54.86% |
| 2015 | -46.85 Million USD | -74.96% |
| 2014 | -26.78 Million USD | -0.28% |
| 2013 | -26.7 Million USD | -20.31% |
| 2012 | -22.19 Million USD | 38.03% |
| 2011 | -35.82 Million USD | -43.66% |
| 2010 | -24.93 Million USD | -28.52% |
| 2009 | -19.4 Million USD | 23.54% |
| 2008 | -25.37 Million USD | -2.44% |
| 2007 | -24.77 Million USD | -19.5% |
| 2006 | -20.72 Million USD | -50.78% |
| 2005 | -13.74 Million USD | 6.16% |
| 2004 | -14.65 Million USD | -24.48% |
| 2003 | -11.76 Million USD | 62.72% |
| 2002 | -31.56 Million USD | -10.98% |
| 2001 | -28.44 Million USD | -127.84% |
| 2000 | -12.48 Million USD | -220.08% |
| 1999 | -3.9 Million USD | -12.78% |
| 1998 | -3.45 Million USD | -157.1% |
| 1997 | -1.34 Million USD | -322.96% |
| 1996 | -318 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -34.03 Million USD | 18.28% |
| 2024 Q1 | -45.37 Million USD | 27.24% |
| 2023 FY | -114.29 Million USD | 43.22% |
| 2023 Q2 | -123.57 Million USD | -191.42% |
| 2023 Q3 | -106.4 Million USD | 13.89% |
| 2023 Q4 | -62.36 Million USD | 41.39% |
| 2023 Q1 | 135.17 Million USD | 344.04% |
| 2022 Q3 | -54.89 Million USD | -20.03% |
| 2022 FY | -201.28 Million USD | -9.79% |
| 2022 Q1 | -45.26 Million USD | -13.44% |
| 2022 Q2 | -45.73 Million USD | -1.05% |
| 2022 Q4 | -55.39 Million USD | -0.91% |
| 2021 Q2 | -48.7 Million USD | -5.18% |
| 2021 Q1 | -46.3 Million USD | -6.61% |
| 2021 Q4 | -39.89 Million USD | 17.63% |
| 2021 Q3 | -48.43 Million USD | 0.54% |
| 2021 FY | -183.33 Million USD | -41.52% |
| 2020 Q2 | -37.89 Million USD | 14.88% |
| 2020 Q1 | -44.52 Million USD | -3130.77% |
| 2020 Q4 | -43.43 Million USD | -1073.52% |
| 2020 Q3 | -3.7 Million USD | 90.23% |
| 2020 FY | -129.55 Million USD | -23.17% |
| 2019 Q2 | -33.5 Million USD | 23.68% |
| 2019 Q4 | 1.46 Million USD | 105.02% |
| 2019 Q3 | -29.24 Million USD | 12.7% |
| 2019 FY | -105.18 Million USD | -36.33% |
| 2019 Q1 | -43.89 Million USD | -111.33% |
| 2018 Q2 | -19.14 Million USD | 8.84% |
| 2018 Q4 | -20.77 Million USD | -27.9% |
| 2018 FY | -77.15 Million USD | -36.89% |
| 2018 Q1 | -20.99 Million USD | -52.53% |
| 2018 Q3 | -16.24 Million USD | 15.15% |
| 2017 Q1 | -16.79 Million USD | -70.82% |
| 2017 Q2 | -12.76 Million USD | 23.96% |
| 2017 Q3 | -13.03 Million USD | -2.09% |
| 2017 Q4 | -13.76 Million USD | -5.61% |
| 2017 FY | -56.36 Million USD | 22.32% |
| 2016 Q3 | -19.2 Million USD | 28.45% |
| 2016 Q1 | -16.68 Million USD | -6.43% |
| 2016 FY | -72.55 Million USD | -54.86% |
| 2016 Q2 | -26.84 Million USD | -60.91% |
| 2016 Q4 | -9.83 Million USD | 48.82% |
| 2015 Q1 | -6.22 Million USD | -39.2% |
| 2015 Q2 | -12.27 Million USD | -97.35% |
| 2015 FY | -46.85 Million USD | -74.96% |
| 2015 Q3 | -12.68 Million USD | -3.32% |
| 2015 Q4 | -15.67 Million USD | -23.56% |
| 2014 Q2 | -7.04 Million USD | 7.41% |
| 2014 FY | -26.78 Million USD | -0.28% |
| 2014 Q3 | -7.65 Million USD | -8.61% |
| 2014 Q4 | -4.46 Million USD | 41.61% |
| 2014 Q1 | -7.61 Million USD | 6.89% |
| 2013 Q1 | -6.9 Million USD | -104.96% |
| 2013 Q3 | -6.15 Million USD | -12.64% |
| 2013 Q4 | -8.17 Million USD | -32.72% |
| 2013 FY | -26.7 Million USD | -20.31% |
| 2013 Q2 | -5.46 Million USD | 20.81% |
| 2012 Q1 | -7.28 Million USD | -14.42% |
| 2012 Q2 | -5.74 Million USD | 21.13% |
| 2012 Q3 | -5.8 Million USD | -1.01% |
| 2012 Q4 | -3.36 Million USD | 41.93% |
| 2012 FY | -22.19 Million USD | 38.03% |
| 2011 Q1 | -9.6 Million USD | -15.15% |
| 2011 Q2 | -10.28 Million USD | -7.08% |
| 2011 Q3 | -9.57 Million USD | 6.88% |
| 2011 Q4 | -6.36 Million USD | 33.52% |
| 2011 FY | -35.82 Million USD | -43.66% |
| 2010 Q4 | -8.33 Million USD | 4.33% |
| 2010 Q1 | -4 Million USD | -65.76% |
| 2010 FY | -24.93 Million USD | -28.52% |
| 2010 Q2 | -3.87 Million USD | 3.1% |
| 2010 Q3 | -8.71 Million USD | -124.67% |
| 2009 Q4 | -2.41 Million USD | 49.73% |
| 2009 Q2 | -5.15 Million USD | 26.58% |
| 2009 Q1 | -7.02 Million USD | -219.46% |
| 2009 Q3 | -4.8 Million USD | 6.86% |
| 2009 FY | -19.4 Million USD | 23.54% |
| 2008 Q2 | -7.98 Million USD | 9.3% |
| 2008 FY | -25.37 Million USD | -2.44% |
| 2008 Q4 | -2.19 Million USD | 65.54% |
| 2008 Q3 | -6.38 Million USD | 20.12% |
| 2008 Q1 | -8.8 Million USD | -15.79% |
| 2007 Q3 | -5.31 Million USD | 8.89% |
| 2007 Q2 | -5.83 Million USD | 2.81% |
| 2007 Q1 | -6 Million USD | 38.74% |
| 2007 Q4 | -7.6 Million USD | -43.02% |
| 2007 FY | -24.77 Million USD | -19.5% |
| 2006 FY | -20.72 Million USD | -50.78% |
| 2006 Q3 | -3.64 Million USD | 10.54% |
| 2006 Q2 | -4.07 Million USD | -26.93% |
| 2006 Q1 | -3.2 Million USD | -9.86% |
| 2006 Q4 | -9.8 Million USD | -169.17% |
| 2005 Q3 | -3.79 Million USD | -9.72% |
| 2005 Q2 | -3.45 Million USD | 3.46% |
| 2005 Q1 | -3.58 Million USD | -5.33% |
| 2005 FY | -13.74 Million USD | 6.16% |
| 2005 Q4 | -2.92 Million USD | 23.0% |
| 2004 FY | -14.65 Million USD | -24.48% |
| 2004 Q1 | -3.17 Million USD | -56.68% |
| 2004 Q2 | 3.39 Million USD | 206.86% |
| 2004 Q3 | -4.67 Million USD | -237.62% |
| 2004 Q4 | -3.39 Million USD | 27.29% |
| 2003 FY | -11.76 Million USD | 62.72% |
| 2003 Q1 | -3.07 Million USD | -196.71% |
| 2003 Q4 | -2.02 Million USD | 31.59% |
| 2003 Q3 | -2.96 Million USD | 19.9% |
| 2003 Q2 | -3.7 Million USD | -20.58% |
| 2002 Q4 | -1.03 Million USD | 95.21% |
| 2002 FY | -31.56 Million USD | -10.98% |
| 2002 Q3 | -21.6 Million USD | -443.17% |
| 2002 Q2 | -3.97 Million USD | 19.67% |
| 2002 Q1 | -4.95 Million USD | -24.58% |
| 2001 Q1 | -3.02 Million USD | 22.05% |
| 2001 FY | -28.44 Million USD | -127.84% |
| 2001 Q4 | -3.97 Million USD | 78.15% |
| 2001 Q3 | -18.19 Million USD | -458.83% |
| 2001 Q2 | -3.25 Million USD | -7.67% |
| 2000 Q2 | -2.71 Million USD | 2.73% |
| 2000 Q1 | -2.78 Million USD | 0.0% |
| 2000 FY | -12.48 Million USD | -220.08% |
| 2000 Q4 | -3.87 Million USD | -24.9% |
| 2000 Q3 | -3.1 Million USD | -14.49% |
| 1999 FY | -3.9 Million USD | -12.78% |
| 1998 FY | -3.45 Million USD | -157.1% |
| 1997 FY | -1.34 Million USD | -322.96% |
| 1996 FY | -318 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -61.96% |
| Dynavax Technologies Corporation | -37.02 Million USD | -639.994% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -5100.323% |
| Perrigo Company plc | 151.9 Million USD | 280.385% |
| Illumina, Inc. | -1.06 Billion USD | 74.368% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 103.995% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 40.506% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.053% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 113.86% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -147.711% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.77% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -513.439% |
| Waters Corporation | 817.67 Million USD | 133.51% |
| Biogen Inc. | 1.29 Billion USD | 121.129% |
| Evolus, Inc. | -49.23 Million USD | -456.547% |
| Adicet Bio, Inc. | -152.03 Million USD | -80.221% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -125.528% |
| bluebird bio, Inc. | -244.26 Million USD | -12.177% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -76.138% |
| FibroGen, Inc. | -281.81 Million USD | 2.771% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 120.297% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -507.856% |
| Homology Medicines, Inc. | -48.25 Million USD | -467.827% |
| Geron Corporation | -193.94 Million USD | -41.28% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 2.895% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -272.826% |
| Myriad Genetics, Inc. | -123.7 Million USD | -121.508% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -171.758% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 46.825% |
| Zoetis Inc. | 3.06 Billion USD | 108.928% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -468.475% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 125.201% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 240.919% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 106.361% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -599.831% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 22.538% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 0.725% |
| Verastem, Inc. | -92.08 Million USD | -197.56% |
| Nektar Therapeutics | -137.42 Million USD | -99.385% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -18.195% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -181.444% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -2.308% |
| OPKO Health, Inc. | -157.02 Million USD | -74.502% |
| Exelixis, Inc. | 170.88 Million USD | 260.345% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 209.209% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 355.406% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -391.436% |
| uniQure N.V. | -282.87 Million USD | 3.134% |
| Imunon, Inc. | -21.03 Million USD | -1202.898% |
| Blueprint Medicines Corporation | -486.27 Million USD | 43.652% |
| Insmed Incorporated | -709.62 Million USD | 61.387% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 181.169% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 30.009% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1427.994% |
| Incyte Corporation | 620.52 Million USD | 144.157% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 62.279% |